Movement Disorders

The potential of nilotinib in the treatment of movement disorders 6:36
The potential of nilotinib in the treatment of movement disorders
Charbel Moussa • 28 Nov 2022
Update on huntingtin-lowering strategies under investigation for Huntington’s disease 4:14
Update on huntingtin-lowering strategies under investigation for Huntington’s disease
Ann Morgan et al. • 16 Sep 2022
Improving CNS delivery and distribution of Huntington’s disease therapies 2:13
Improving CNS delivery and distribution of Huntington’s disease therapies
Ann Morgan et al. • 16 Sep 2022
The impact of wild-type HTT suppression on brain function 0:50
The impact of wild-type HTT suppression on brain function
Ann Morgan et al. • 16 Sep 2022
Botulinum neurotoxin for the treatment of essential tremor 0:51
Botulinum neurotoxin for the treatment of essential tremor
Sanjay Pandey • 16 Sep 2022
Updates on α-synuclein as a biomarker in Parkinson’s disease 1:10
Updates on α-synuclein as a biomarker in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Development of novel trial outcomes in Parkinson’s disease 1:42
Development of novel trial outcomes in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Poststroke movement disorders: challenges & future research 2:43
Poststroke movement disorders: challenges & future research
Sanjay Pandey • 16 Sep 2022
Tackling sleep disturbances in Parkinson’s disease 1:33
Tackling sleep disturbances in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Prodromal Parkinson’s disease: identification & ethical issues 1:09
Prodromal Parkinson’s disease: identification & ethical issues
Gennaro Pagano • 17 Sep 2022
Systems underlying music-induced paradoxical movement in Parkinson’s disease 3:36
Systems underlying music-induced paradoxical movement in Parkinson’s disease
Bin Hu • 12 Sep 2022
Effects of apomorphine sublingual film on QT interval in patients with Parkinson’s disease 0:53
Effects of apomorphine sublingual film on QT interval in patients with Parkinson’s disease
Fabrizio Stocchi • 16 Sep 2022
Implementing device-aided treatment strategies in advanced Parkinson’s disease 1:04
Implementing device-aided treatment strategies in advanced Parkinson’s disease
Eric Freire-Alvarez • 15 Sep 2022
Subcutaneous levodopa/carbidopa infusion for Parkinson’s disease 0:50
Subcutaneous levodopa/carbidopa infusion for Parkinson’s disease
Eric Freire-Alvarez • 15 Sep 2022
Targeting α-synuclein & neuroinflammation in Parkinson’s disease 1:26
Targeting α-synuclein & neuroinflammation in Parkinson’s disease
Fabrizio Stocchi • 16 Sep 2022
In-home remote assessment of the MDS-UPDRS Part III: development a guide for patients 5:23
In-home remote assessment of the MDS-UPDRS Part III: development a guide for patients
Michelle Tosin • 23 Sep 2022
The content of VJNeurology is intended for healthcare professionals